Lilly in February announced plans to add four U.S. manufacturing sites at yet-to-be-determined sites as part of a roughly $27 billion investment.

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

The Woodlands Township Board of Directors has agreed to begin exploring what it would take to recruit a luxury hotel brand ...

Compounding pharmacies, that produced the weight loss drugs at a fraction of their brand name price, are being forced to stop ...

Discover why LXP Industrial Trust is a top income/value pick with a 6.6% yield, growth-focused portfolio, and exposure to ...

CRISPR Therapeutics announced an agreement with Sirius Therapeutics to develop and commercialize small interfering RNA (siRNA ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

Eli Lilly (NYSE: LLY) has transformed from a steady pharmaceutical giant into one of Wall Street’s standout growth ...

Eli Lilly is expanding its pain drug pipeline with the acquisition of SiteOne Therapeutics, a startup whose lead program addresses the same target as a Vertex Pharmaceuticals product whose ...